quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 19, 2026

Kevin O'Leary Reveals He's Still Long Bitcoin Despite The 'Brutal Correction,' But Warns About 'Something Bigger' Happening Underneath

View original at finance.yahoo.com
Kevin O'Leary Reveals He's Still Long Bitcoin Despite The 'Brutal Correction,' But Warns About 'Something Bigger' Happening Underneath Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BlackRock recommends Bitcoin allocation of 1% to 2% in multi-asset portfolios

    80% confidence

  • Convincing nations and fiduciary organizations to invest in Bitcoin is already difficult, and quantum uncertainty makes it worse

    80% confidence

  • Quantum computing risks are making institutional investors hesitate to increase Bitcoin allocation beyond 3%

    80% confidence

  • Swift deployment of quantum-resistant technology is needed for Ethereum's long-term cryptographic safety

    80% confidence

  • May 15 is predicted as the passage date for cryptocurrency legislation

    80% confidence

  • Something bigger is happening underneath the Bitcoin price action beyond the correction

    80% confidence

  • Kevin O'Leary is still long on Bitcoin despite the brutal 50% correction

    80% confidence

  • Cryptocurrency market structure legislation will be passed before midterm elections

    80% confidence

Data points we hold from this source

Elf Labs · international markets30 countries
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Kevin O'Leary Reveals He's Still Long Bitcoin Despite The 'Brutal Correction,' But Warns About 'Something Bigger' Happening Underneath — Source | Via News | pt.VIA.NEWS